Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05522660RecruitingPhase 3
Immunotherapy or targeted therapy with focused brain radiation
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
NaplesAges 18 years+ - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT06071013RecruitingPhase 1/Phase 2
Nintedanib plus EGFR inhibitor for EGFR-mutated lung cancer
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
TaichungAges 20–70 - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06405230RecruitingPhase 1/Phase 2
Study of Immunotherapy Response in Returned Lung Cancer
This trial tests how well a new imaging method and lab-grown tumor models can predict response to immunotherapy in people with non-small cell lung cancer that has returned after initial surgery. Participants will receive standard immunotherapy, and researchers will study their tumor samples and scans.
LondonAges 30 years+ - NCT06496490RecruitingPhase 2
TQB2102 for HER2-mutated non-small cell lung cancer
This trial tests a new drug, TQB2102, for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene and has stopped responding to standard treatments. It aims to see if the drug can shrink or slow the cancer.
Fuzhou, FujianAges 18–75 - NCT06659042RecruitingPhase 2
Tislelizumab before and after surgery for KRAS-mutated lung cancer
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06706713RecruitingPhase 2
Testing BEBT-109 for advanced EGFR exon 20 lung cancer
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06800339RecruitingPhase 1
Immunotherapy and radiation before surgery for lung cancer
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Baltimore, MarylandAges 18 years+ - NCT06829459RecruitingPhase 3
New drug combo vs chemo for resistant lung cancer
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06931717RecruitingPhase 3
Immunotherapy after lung cancer surgery for those not getting chemo
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
ViennaAges 18 years+ - NCT07098338RecruitingPhase 2
New drug combos for advanced lung cancer
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Santa Monica, CaliforniaAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07130916RecruitingPhase 1
Aumolertinib study for European patients with lung cancer
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
Banja LukaAges 18 years+ - NCT07323056RecruitingPhase 2
Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
ShanghaiAges 18 years+ - NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT07489716RecruitingPhase 2
Study of SHR-1826 for advanced non-small cell lung cancer
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Jinan, ShandongAges 18–75 - NCT06822543RecruitingPhase 2
A new treatment for lung cancer that has spread to the brain
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
São José do Rio Preto, São PauloAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,558 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.